NCT04665076 2020-12-11Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell TumorsHebei Senlang Biotechnology Inc., Ltd.Phase NA Unknown60 enrolled